Avant Diagnostics, Inc. (OTC: AVDX) is a medical diagnostic
technology company specializing in large panel biomarker screening. The
company’s first test, OvaDx®, is being developed in conjunction with Arrayit
Corporation (OTCQB: ARYC) as the market’s first large panel biomarker screening
test for pre-symptomatic ovarian cancer. In preclinical research studies, OvaDx
demonstrated high sensitivity and specificity for all types and stages of
ovarian cancer – including stage IA-IV borderline serous, clear cell,
endometrioid, mixed epithelial, mucinous, serous and ovarian adenocarcinoma.
Upon reception of FDA 510(k) clearance for OvaDx, Avant intends to sell or
license the innovative technology as a diagnostic test for women seeking
greater wellness.
When commercialized, the market for Avant’s sophisticated
microarray-based test is likely to be immense. According to statistics from the
American Cancer Society, ovarian cancer ranks fifth in terms of cancer deaths
among women, accounting for more deaths than any other cancer of the female
reproductive system. In 2015, it’s estimated that more than 21,200 women will
receive a new diagnosis of ovarian cancer in the United States. For these
women, early diagnosis can be pivotal to surviving the disease. If diagnosed in
stage I, the five-year survivability rate of ovarian cancer is 90 percent, but
that statistic falls to 70 percent if diagnosis occurs in stage II, further
demonstrating the considerable market need for highly sensitive testing
technology such as OvaDx.
Avant is led by a management team with decades of related
industry experience. The company’s president and chief executive officer, Gregg
Linn, has been with Avant since December 2012. Prior to serving in this
position, Linn held similar positions at two firms specializing in providing
strategic financial and business development advisory services to public and
non-public businesses.
Moving forward, Avant will look to lean on its experienced
management team in order to continue making progress toward the commercialization
of its groundbreaking OvaDx diagnostic tool. In April, the company announced
the engagement of DOCRO, Inc. to manage the preparation and submission of
required data as necessary to obtain a 510(k) clearance for OvaDx as an aid in
monitoring women diagnosed with ovarian cancer. For prospective shareholders,
this progress could foreshadow an opportunity for considerable financial growth
in the future.
For more information, visit www.avantdiagnostics.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment